Review Article
COVID-19 Vaccine Acceptance Level in Ethiopia: A Systematic Review and Meta-Analysis

Addisu Tadesse Sahile,1 Girma Demissie Gizaw,2 Tennyson Mgutshini,3 Zewdu Minwuyelet Gebremariam,4 and Getabilew Endazenaw Bekele5

1Department of Public Health, Unity University, Addis Ababa, Ethiopia
2Department of Public Health Emergency Management, Ethiopian Public Health Institute, Addis Ababa, Ethiopia
3Department of Public Health, University of South Africa, Pretoria, South Africa
4Department of Biomedical Science, Kotobe Metropolitan University, Addis Ababa, Ethiopia
5Department of Public Health, Yekatit 12 Hospital Medical College, Addis Ababa, Ethiopia

Correspondence should be addressed to Addisu Tadesse Sahile; sahdis91@gmail.com

Received 7 March 2022; Revised 10 May 2022; Accepted 29 July 2022; Published 25 August 2022

Academic Editor: Aseer Manilal

Copyright © 2022 Addisu Tadesse Sahile et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The coronavirus disease 2019 pandemic has had a devastating impact on the everyday lives of the world’s population and to this end, the development of curative vaccines was upheld as a welcome panacea. Despite the undeniable negative impact of the disease on human beings, lower than expected proportions of people have taken up the vaccines, particularly in the developing non-Western world. Ethiopia represents an interesting case example, of a nation where COVID-19 vaccine acceptance levels have not been well investigated and a need exists to assess the overall level of vaccine acceptance.

Methods. A systematic multidatabase search for relevant articles was carried out across Google Scholar, Web of Science, Science Direct, Hinari, EMBASE, Boolean operator, and PubMed. Two reviewers independently selected, reviewed, screened, and extracted data by using a Microsoft Excel spreadsheet. The Joanna Briggs Institute prevalence critical appraisal tools and the modified NewcastleOttawa Scale (NOS) were used to assess the quality of evidence. All studies conducted in Ethiopia, reporting vaccine acceptance rates were incorporated. The extracted data were imported into the comprehensive meta-analysis version 3.0 for further analysis. Heterogeneity was confirmed using Higgins’s method, and publication bias was checked by using Beggs and Eggers tests. A random-effects meta-analysis model with a 95% confidence interval was computed to estimate the pooled prevalence. Furthermore, subgroup analysis based on the study area and sample size was done. Results and Conclusion. After reviewing 67 sources, 18 articles fulfilled the inclusion criteria and were included in the meta-analysis. The pooled prevalence of COVID-19 vaccine acceptance in Ethiopia was 57.8% (95% CI: 47.2%–67.8%). The level of COVID-19 vaccine acceptance in Ethiopia was at a lower rate than necessary to achieve herd immunity. The highest level of vaccine acceptance rate was reported via online or telephone surveys followed by the southern region of Ethiopia. The lowest vaccine acceptance patterns were reported in Addis Ababa.

1. Introduction
The coronavirus (COVID)-19 disease is caused by a highly contagious acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and for several months after its emergence, no proven vaccine was available. Globally, the fatality rate of COVID-19 infection was estimated at 0.5% to 1% [1]. Its negative impact reached the everyday lives of all human beings globally [2–5] to the extent of disrupting the normal economic and social activities of the world’s population [6–10]. In response, global communities took different measures to contain its spread, and these included lockdowns and border closures [11–13].

There has been an implementation of various public health measures that included hand hygiene, lockdowns, and social distancing in most parts of the world. Even so, the overall impact of these COVID-19 disease prevention measures has varied from one set to the other [14].
Medically, vaccines have been separated from other preventative measures on the basis of their superior prevention and disease control profiles [15, 16]. Even so, their uptake remains an issue of contention.

Barriers to vaccine acceptance are complex; moreover, they are context-specific and fluctuate across the place, time, and vaccine type [17]. However, there has been a continuous distribution of COVID-19 vaccines across the world population including Ethiopia. That said, hesitation against vaccines represents the single most notable obstacle to having adequate coverage across various populations. Vaccine hesitation was identified by the World Health Organization as one of the top global health threats as of the year 2019 [18].

The corpus of evidence related to COVID-19 vaccine acceptance suggests that a considerable portion of people are opposed to the vaccine. A global report on COVID-19 vaccine acceptance reported the acceptance rate to be under 67% [19].

Notably, most reports in Ethiopia show lower vaccine coverage. Additionally, the lack of specified investigation of the above strongly points to an acknowledgment that, the overall level of COVID-19 vaccine acceptance in Ethiopia represents a poorly investigated phenomenon. Guided by this, this meta-analysis offers an assessment of the overall level of vaccine acceptance in Ethiopia.

1.1. Question. What is the overall level of COVID-19 vaccine acceptance in Ethiopia?

2. Methods

2.1. Reporting. The preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline [20] was used as a reporting framework within this meta-analysis (additional file 1 S1).

2.2. Searching Strategies. The PRISMA systematic review protocol was followed as a reporting guideline and eligible studies for the analysis were selected in terms of abstracts, titles, and then for full articles on the basis of the inclusion criteria. EMBASE, PubMed, Hinari, Google Scholar, Web of Science, Science Direct, and African Journals Online were systematically searched to identify articles that included Medical Subject Headings and free-text languages. These databases were searched by using both controlled and free-text languages. In terms of free-text searches, the keywords included the following combination of terms: (Willingness, OR COVID-19 Vaccine OR Acceptance) AND Ethiopia. The controlled searches included the following Medical Subject Headings (MeSH) terms: "COVID-19 Vaccine Acceptance" and "Ethiopia" as recommended for each database. Search terms were used individually and in combination using "AND" and "OR" Boolean operators. The search was guided by PICO, a population that was intended to take the vaccine.

2.3. Inclusion and Exclusion Criteria. The following types of studies from 2019 to 2022 were included; study populations comprised any age group, study outcome was "willingness or intention to take vaccine or vaccine acceptance," study design is cross-sectional and studies written in English were included. However, in this systematic review and meta-analysis; qualitative studies and data on those who took the vaccine were excluded.

2.4. Outcome of Interest: PICO. The population of the study was any age group and the outcome of interest was vaccine acceptance which thus was reported as "Are you willing to take COVID-19 Vaccine if available to you?" and measured as yes and no or willing versus unwilling. The level of vaccine acceptance was presented as a frequency and percentage.

2.5. Screening and Data Extraction. Screening for titles and abstracts against the inclusion was conducted by the two reviewers (SAT and GGD). Furthermore, an independent assessment was made for the full-text articles based on the predetermined inclusion criteria. Inconsistencies across the reviewers were dealt with via a discussion and consensus-seeking engagements involving all the investigators. Data extraction was made by three authors (TM, GZM, and BGE) independently from a random sample of 20% of the papers to check consistency and cross variation.

2.6. Study Quality Assessment. A structured data abstraction form was constructed in Microsoft Excel. Attention was given to clarity of data, objective, study design, population, sample size, and proportion of vaccine acceptance (Table 1). The modified version of the Newcastle-Ottawa Scale for the cross-sectional study [39] was used for the methodological qualities of each article. Additionally, studies were critically appraised with the Joanna Briggs Institute prevalence critical appraisal tool [40].

2.7. Data Synthesis and Statistical Analysis. Data were extracted using a Microsoft Excel spreadsheet and imported to comprehensive meta-analysis version3.0 software for further analysis. The pooled effect size with a 95% confidence interval of national COVID-19 vaccine acceptance; a rate that was determined using a weighted inverse variance random-effects model. The $I^2$ statistic; 25, 50, and 75% representing a low, moderate, and high heterogeneity consecutively assessed the heterogeneity across the studies [41], whereas the publication bias was evaluated by funnel plot and Eggers and Beggs test [42].

3. Result

3.1. Selection of the Studies. A comprehensive literature search of the databases yielded a total of 67 published articles, of which 20 articles were retrieved from Google Scholar, 13 articles from PubMed, 12 articles from African Journals online, 7 articles from Hinari, and 15 articles from EMBASE, Web of Science, and Science Direct. Thirty-one articles were excluded for duplication and scope. The other 18 articles were excluded for failing to offer reports on the outcome. A total of 18 full-text articles that fulfilled the
eligibility criteria with a total sample size of 10873 were included in the final analysis for the systematic review and meta-analysis (Figure 1).

3.2. Characteristics of the Included Studies. Pertinent data relating to “year of publication,” authors, the outcome, and sample sizes with other main findings from the selected articles were extracted and presented in Table 1. All articles were cross-sectional and conducted in Ethiopia. The studies were distributed in southern region [21, 27–29, 31], Addis Ababa [22–24, 36], Amhara region [25, 26, 30, 33, 37], and online or telephone. [32, 34, 35, 38]. The sample size of the selected studies ranged from 301 to 2178 (Table 1).

3.3. Subgroup Analysis. According to the subgroup analysis report, the highest level of vaccine acceptance (68.7%; 95% CI: 34.1%–90.3%) was reported in online or telephone surveys whilst the lowest level of vaccine acceptance (51.8%; 95% CI: 33.3%–69.8%) was reported in Addis Ababa. Regarding the sample size, the highest level of vaccine acceptance (74.0%; 95% CI: 23.5%–96.4%) was reported in studies with a sample size of larger than 800 (Table 2).

3.4. COVID-19 Vaccine Acceptance. In this systematic review and meta-analysis, the pooled estimate of the COVID-19 vaccine acceptance rate was illustrated via a forest plot. The pooled prevalence of vaccine acceptance in Ethiopia was 57.8% (95% CI: 47.2%–67.8%) (Figure 2).

3.5. Assessment of Publication Bias. A symmetrical funnel plot was observed. Begg’s and Egger’s tests showed the absence of significant publication bias at a p value of >0.05 (Figure 3).

3.6. Heterogeneity. For the identification of the possible causes of variation across different studies, meta-regression analysis was conducted using sample size and study area. The result showed that there was no significant heterogeneity across the studies (p > 0.05) (Table 3).

4. Discussion

The current systematic review and meta-analysis provided critical evidence on the level of COVID-19 vaccine acceptance in Ethiopia. This study found the overall level of vaccine acceptance in Ethiopia to be at 58.7%. This was consistent with the findings of 48.93% in Africa [43], 58.5% in low and middle income countries [44], 20.0% to 58.2% in Nigeria [45], 48% among adults in Saudi Arabia [46], 67% among adults in Kuwait [47], 62.6% in Jordan [48], 63% in Hong Kong [49], 65.75% in Japan [50], 53% in Pakistan [51], 61.7% in Iraq [52], 65.6% in Qatar [53], and 51.6% in Turkey [54]. The finding from this study was also consistent with the results from 64% in the UK [56], 63.5% in Kenya [55], and 50.2% in Nigeria [56].

By contrast, the level of vaccine acceptance was reported in different countries. These included Malawi with an overall prevalence of 82.7% [57], 71.4% in Mozambique [58], 84.9% in Rwanda [59], 71.0% in Côte d’Ivoire [60], 75.3% in China [61], 74.65% among adults in Bangladesh [62], 85% in Israel [63], 91.3% of adults in China [15], 94.3% in Malaysia [64], and 91.5% in Italy [65]. This variation might be due to variation in the availability of vaccine type and population characteristics.

The vaccine acceptance level was higher in different countries including 78% in Scotland [69], 78.5% in Greece [70], 75% in Portugal [71], 77.65% in France [72], 68.5% in the United States [73], 80% in Canada [74], 90.1% in South

| Author          | Year | Region                  | Sample size | Prevalence (%) |
|-----------------|------|-------------------------|-------------|----------------|
| Abebe et al.    | 2021 | Southern, (Gurage)      | 492         | 62.60          |
| Mohammed et al. | 2021 | Addis Ababa             | 614         | 39.70          |
| Tadele Admasu   | 2021 | Addis Ababa             | 422         | 42.30          |
| Sahile et al.   | 2022 | Addis Ababa             | 407         | 39.80          |
| Tsegaw et al.   | 2021 | Debre Berhan            | 423         | 69.30          |
| Handebo et al.  | 2021 | Gondar                  | 301         | 54.80          |
| Mose and Yeshaneh | 2021 | Southwest (Wolkite)    | 396         | 70.70          |
| Mose [28]       | 2021 | Southern                | 630         | 61.0           |
| Hailiemariam et al. [29] | 2021 | Southwest              | 412         | 31.30          |
| Aemro et al.    | 2021 | Northwest               | 440         | 54.10          |
| Mose et al. [31] | 2021 | Northwest               | 420         | 58.80          |
| Belsti al. [32] | 2021 | Online                  | 1184        | 31.40          |
| Zeleke and Bayeh [33] | 2021 | Northwest              | 538         | 29.00          |
| Rikitu Terefa et al. [34] | 2021 | Online                 | 522         | 62.10          |
| Oyekale [35]   | 2021 | Telephone               | 2178        | 92.30          |
| Dereje et al.   | 2021 | Addis Ababa             | 422         | 80.90          |
| Adane et al.    | 2021 | Northeast (Dessie)      | 404         | 64.0           |
| Bereket et al.  | 2021 | Online                  | 668         | 72.20          |
Table 2: Level of COVID-19 vaccine acceptance by study area and sample size.

| Variables | Characteristics | Included studies | Sample size | Prevalence (95% CI) |
|-----------|-----------------|------------------|-------------|---------------------|
| Area      |                 |                  |             |                     |
|           | Addis Ababa     | 4                | 1865        | 51.8% (33.3%–69.8%) |
|           | Amhara          | 5                | 2106        | 54.2% (39.4%–68.3%) |
|           | Southern        | 5                | 2350        | 57.0% (44.4%–68.7%) |
|           | Other (online/telephone) | 4 | 4552 | 68.7% (34.1%–90.3%) |
| Sample size |                 |                  |             |                     |
|            | <400            | 2                | 697         | 63.5% (59.8%–67.0%) |
|            | 400–800         | 13               | 6814        | 55.2% (46.7%–63.4%) |
|            | >800            | 3                | 3362        | 74.0% (23.5%–96.4%) |

Study Name Event rate and 95% CI

| Study Name | Event rate | Lower limit | Upper limit | Relative weight |
|------------|------------|-------------|-------------|-----------------|
| Haimanot Abebe et al, 2021 | 0.626 | 0.582 | 0.668 | 5.56 |
| Rihanna Mohammed et al, 2021 | 0.397 | 0.359 | 0.436 | 5.57 |
| Fitalew Tadele Admasu, 2021 | 0.423 | 0.377 | 0.471 | 5.55 |
| Addisu Tadesse Sahile et al, 2022 | 0.398 | 0.352 | 0.446 | 5.55 |
| Birhan Tsegaw et al, 2021 | 0.693 | 0.647 | 0.735 | 5.54 |
| Ayenew Mose and Alex Yeshaneh, 2021 | 0.707 | 0.660 | 0.750 | 5.54 |
| Ayenew Mose, 2021 | 0.610 | 0.571 | 0.647 | 5.57 |
| Shewangizaw Hailemariam et al, 2021 | 0.313 | 0.270 | 0.359 | 5.54 |
| Agazhe Aemro et al, 2021 | 0.541 | 0.494 | 0.587 | 5.56 |
| Ayenew Mose et al, 2021 | 0.585 | 0.537 | 0.631 | 5.55 |
| Yitayeh Befeti et al, 2021 | 0.314 | 0.288 | 0.341 | 5.59 |
| Agerie Mengistie Zeleke et al, 2021 | 0.290 | 0.253 | 0.330 | 5.56 |
| Dufera Rikitu Terefa et al, 2021 | 0.621 | 0.579 | 0.662 | 5.56 |
| Abayomi Samuel Oyekale, 2021 | 0.923 | 0.911 | 0.933 | 5.58 |
| Nefiyu Dereje et al, 2021 | 0.809 | 0.769 | 0.844 | 5.52 |
| Metadel Adane et al, 2021 | 0.640 | 0.592 | 0.685 | 5.55 |
| Bereket A Guan gul et al, 2021 | 0.722 | 0.687 | 0.755 | 5.57 |
| Simegnew Handebo et al, 2021 | 0.548 | 0.491 | 0.603 | 5.53 |
| | 0.578 | 0.472 | 0.678 | |

Meta Analysis

Figure 2: Forest plot for the pooled prevalence of COVID-19 vaccine acceptance.
Authors’ Contributions

SAT and TM were involved in the development of the protocol, design, selection of the study, data extraction, statistical analysis, and development of the initial draft of the manuscript. GGD, GZM, and BGE got involved in the preparation and editing of the final draft of the manuscript. All authors read and approved the final draft of the manuscript.

References

[1] T. W. Russell, J. Hellewell, C. I. Jarvis et al., “Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the diamond princess cruise ship, February 2020,” Euro Surveillance, vol. 25, no. 12, Article ID 2000256, 2020.
[2] S. W. Patrick, L. E. Henkhaus, J. S. Zickafoose et al., “Well-being of parents and children during the COVID-19 pandemic: a national survey,” Pediatrics, vol. 146, no. 4, Article ID e2020016824, 2020.
[3] F. Aslam, T. M. Awan, J. H. Syed, A. Kashif, and M. Parveen, “Sentiments and emotions evoked by news headlines of coronavirus disease (COVID-19) outbreak,” Humanities and Social Sciences Communications, vol. 7, no. 1, pp. 23–29, 2020.
[4] S. Pišot, I. Milovanovic, B. Šimunić et al., “Maintaining everyday life praxis in the time of COVID-19 pandemic measures (ELP-COVID-19 survey),” The European Journal of Public Health, vol. 30, no. 6, pp. 1181–1186, 2020.
[5] L. K. Lades, K. Laffan, M. Daly, and L. Delaney, “Daily emotional well-being during the COVID-19 pandemic,” British Journal of Health Psychology, vol. 25, no. 4, pp. 902–911, 2020.
[6] W. McKibbin and R. Fernando, “The economic impact of COVID-19,” Economics in the Time of COVID-19, CEPR Press, Washington, DC, USA, 2020.
[7] Z. Yu, A. Razzaq, A. Rehman, A. Shah, K. Jameel, and R. S. Mor, “Disruption in global supply chain and socioeconomic shocks: a lesson from COVID-19 for sustainable production and consumption,” Operations Management Research, vol. 14, pp. 1–16, 2021.
[8] K. Das, “Impact of COVID-19 pandemic into solar energy generation sector,” 2020, https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3580341.
[9] M. Mofijur, I. R. Fattah, M. A. Alam et al., “Impact of COVID-19 on the social, economic, environmental and energy domains: lessons learnt from a global pandemic,” Sustainable Production and Consumption, vol. 26, 2020.
[10] S. Qiao, D. B. Friedman, C. C. Tam, C. Zeng, and X. Li, “Vaccine acceptance among college students in South Carolina: do information sources and trust in information make a difference?” medRxiv, vol. 12, Article ID 20242982, 2020.
[11] D. Koh, “COVID-19 lockdowns throughout the world,” Occupational Medicine, vol. 70, no. 5, p. 322, 2020.
[12] M. A. Lake, “What we know so far: COVID-19 current clinical knowledge and research,” Clinical Medicine, vol. 20, no. 2, pp. 124–127, 2020.
[13] B. Dariya and G. P. Nagaraju, ”Understanding novel COVID-19: its impact on organ failure and risk assessment for diabetic and cancer patients,” Cytokine & Growth Factor Reviews, vol. 53, pp. 43–52, 2020.
[14] M.-K. Looi, “Covid-19: is a second wave hitting Europe?” BMJ, vol. 371, 2020.
[15] J. Wang, R. Jing, X. Lai et al., “Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China,” Vaccines, vol. 8, no. 3, p. 482, 2020.
[16] H. Harapan, A. L. Wagner, A. Yufika et al., “Acceptance of a COVID-19 vaccine in Southeast Asia: a cross-sectional study in Indonesia,” Frontiers in Public Health, vol. 8, p. 381, 2020.
[17] S. B. Omer, D. A. Salmon, W. A. Orenstein, M. P. Dehart, and N. Halsey, “Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases,” New England Journal of Medicine, vol. 360, no. 19, pp. 1981–1988, 2009.

[18] W. H. Organization, “Ethiopia introduces COVID-19 vaccine in a national launching ceremony,” 2021, https://www.afro.who.int/news/ethiopia-introduces-covid-19-vaccine-national-launching-ceremony.

[19] W. Feleszko, P. Lewulis, A. Czarnecki, and P. Waszkiewicz, “Flattening the curve of COVID-19 vaccine rejection—a global overview,” Vaccines, vol. 9, 2020.

[20] D. Moher, A. Liberati, J. Tetzlaff, D. G. A. Altman, and P. Group, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” PLoS Medicine, vol. 6, no. 7, Article ID e1000097, 2009.

[21] H. Abebe, S. Shitu, and A. Mose, “Understanding of COVID-19 vaccine knowledge, attitude, acceptance, and determinates of COVID-19 vaccine acceptance among adult population in Ethiopia,” Infection and Drug Resistance, vol. 14, pp. 2015–2025, 2021.

[22] R. Mohammed, T. M. Nguse, B. M. Habte, A. M. Fentie, and H. Abebe, S. Shitu, and A. Mose, “Understanding of COVID-19 vaccine acceptance and its associated factors among health workers attitude towards SARS-COVID-2 vaccine, Ethiopia,” BMC Public Health, vol. 22, no. 1, Article ID e0147601, 2016.

[23] G. B. Gebretekle, “COVID-19 vaccine hesitancy in Addis Ababa, Ethiopia: a mixed-methods study,” medRxiv, vol. 12, 2021.

[24] M. M. Patwary, M. A. Alam, M. Bardhan et al., “COVID-19 vaccine acceptance among healthcare workers in northeastern Ethiopia,” BMC Public Health, vol. 22, no. 1, pp. 128–214, 2022.

[25] Z. Munn, S. Moola, D. Riitano, and K. Lisy, “The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence,” International Journal of Health Policy and Management, vol. 3, no. 3, pp. 123–128, 2014.

[26] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” BMJ, vol. 327, no. 7414, pp. 557–560, 2003.

[27] B. T. Tsegaw, F. K. Amogne, T. L. Demisse et al., “Coronavirus disease 2019 vaccine acceptance and perceived barriers among university students in northeast Ethiopia: a cross-sectional study,” Clinical epidemiology and global health, vol. 12, Article ID 100848, 2021.

[28] S. Handebo, M. Wolde, K. Shitu, and A. Kassie, “Determinant of intention to receive COVID-19 vaccine among school teachers in Gondar city, Northwest Ethiopia,” PLoS One, vol. 16, no. 6, Article ID e0253499, 2021.

[29] A. Mose and A. Yeshaneh, “COVID-19 vaccine acceptance and its associated factors among pregnant women attending antenatal care clinic in southwest Ethiopia: institutional-based cross-sectional study,” International Journal of General Medicine, vol. 14, pp. 2385–2395, 2021.

[30] A. Mose, “Willingness to receive COVID-19 vaccine and its determinant factors among lactating mothers in Ethiopia: a cross-sectional study,” Infection and Drug Resistance, vol. 14, pp. 4249–4259, 2021.

[31] S. Hailemariam, B. Mekonnen, N. Shifera et al., “Predictors of pregnant women’s intention to vaccinate against coronavirus disease 2019: a facility-based cross-sectional study in southwest Ethiopia,” SAGE open medicine, vol. 9, Article ID 205031212103834, 2021.

[32] A. Aemro, N. S. Amare, B. Shetie, B. Chekol, and M. Wassie, “Determinants of COVID-19 vaccine hesitancy among health care workers in Amhara region referral hospitals, Northwest Ethiopia: a cross-sectional study,” Epidemiology and Infection, vol. 149, 2021.

[33] A. Mose, K. Haile, and A. Timerga, “COVID-19 vaccine hesitancy among medical and health science students attending Wolkite university in Ethiopia,” PLoS One, vol. 17, no. 1, Article ID e0263081, 2022.

[34] Y. Belšti, Y. Y. Gela, Y. Akalu et al., “Willingness of Ethiopian population to receive COVID-19 vaccine,” Journal of Multidisciplinary Healthcare, vol. 14, pp. 1233–1243, 2021.

[35] A. M. Zeleke and G. M. Bayeh, “Knowledge, attitude and practice towards COVID-19 and associated factors among pregnant women at debark town northwest Ethiopia: an institutional-based cross-sectional study,” World Journal of Advanced Science and Technology, vol. 1, 2022.

[36] R. Mohammed, T. M. Nguse, B. M. Habte, A. M. Fentie, and H. Abebe, S. Shitu, and A. Mose, “Understanding of COVID-19 vaccine acceptance and perceived barriers among COVID-19 vaccine uptake and associated factors among health professionals in Ethiopia,” Infection and Drug Resistance, vol. 14, pp. 5531–5541, 2021.

[37] A. S. Oyekale, “Willingness to take COVID-19 vaccines in Ethiopia: an instrumental variable probit approach,” International Journal of Environmental Research and Public Health, vol. 18, no. 17, p. 8892, 2021.

[38] N. Dereje, A. Tesfaye, B. Tamene et al., “COVID-19 vaccine hesitancy in Addis Ababa, Ethiopia: a mixed-methods study,” medRxiv, vol. 12, 2021.

[39] M. Adane, A. Ademas, and H. Kloos, “Knowledge, attitudes, and perceptions of COVID-19 vaccine and refusal to receive COVID-19 vaccine among healthcare workers in northeastern Ethiopia,” BMJ, vol. 22, no. 1, pp. 128–214, 2022.

[40] Z. Munn, S. Moola, D. Riitano, and K. Lisy, “The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence,” International Journal of Health Policy and Management, vol. 3, no. 3, pp. 123–128, 2014.

[41] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Comparison of two methods to detect publication bias in meta-analysis,” JAMA, vol. 295, no. 6, pp. 676–680, 2006.

[42] A. D. Wake, “The acceptance rate toward COVID-19 vaccine in Africa: a systematic review and meta-analysis,” Global Pediatric Health, vol. 8, Article ID 2333794X2110487, 2021.

[43] M. M. Patwary, M. A. Alam, M. Bardhan et al., “COVID-19 vaccine acceptance among low-and lower-middle-income countries: a rapid systematic review and meta-analysis,” Vaccines, vol. 10, no. 3, p. 427, 2022.

[44] O. Olu-Abiodun, O. Abiodun, and N. Okafor, “COVID-19 vaccination in Nigeria: a rapid review of vaccine acceptance rate and the associated factors,” PLoS One, vol. 17, no. 5, Article ID e0267691, 2021.
Canadian Journal of Infectious Diseases and Medical Microbiology

B. Z. Al-Metwali, A. A. Al-Jumaili, Z. A. Al-Alag, and R. Al-Mulla, M. Abu-Madi, Q. M. Talafha, R. F. Tayyem, and T. Yoda and H. Katsuyama, “Willingness to receive COVID-19 vaccination in Japan,” *Vaccines*, vol. 9, no. 1, p. 48, 2021.

F. A. Chaudhary, B. Ahmad, M. D. Khalid, A. Fazal, M. M. Javaid, and D. Q. Butt, “Factors influencing COVID-19 vaccine hesitancy and acceptance among the Pakistani population,” *Human Vaccines & Immunotherapeutics*, vol. 17, no. 10, pp. 3365–3370, 2021.

B. Z. Al-Metwali, A. A. Al-Jumaili, Z. A. Al-Alag, and B. Sorofman, “Exploring the acceptance of COVID-19 vaccine among healthcare workers and general population using health belief model,” *Journal of Evaluation in Clinical Practice*, vol. 27, no. 5, pp. 1112–1122, 2021.

R. Al-Mulla, M. Abu-Madi, Q. M. Talalha, R. F. Tayyem, and A. M. Abdallah, “COVID-19 vaccine hesitancy in a representative sector population in Qatar,” *Vaccines*, vol. 9, no. 6, p. 665, 2021.

H. İkışık, M. Afif Sezerol, Y. Taşçı, and I. Maral, “COVID-19 vaccine hesitancy: a community-based research in Turkey,” *International Journal of Clinical Practice*, vol. 75, no. 8, Article ID e14336, 2021.

S. Orangi, J. Pinchoff, D. Mwangi et al., “Assessing the level and determinants of COVID-19 vaccine confidence in Kenya,” *Vaccines*, vol. 9, no. 8, p. 936, 2021.

E. Alice Tobin, M. Okonofua, A. Adeke, and A. Obi, “Willingness to accept a COVID-19 vaccine in Nigeria: a population-based cross-sectional study,” *Central African Journal of Public Health*, vol. 7, no. 2, p. 53, 2021.

S. Kanyanda, Y. Markhof, P. Wollburg, and A. Zezza, “Acceptance of COVID-19 vaccines in sub-Saharan Africa: evidence from six national phone surveys,” *BMJ Open*, vol. 11, no. 12, Article ID e055159, 2021.

J. Dula, A. Mulhanga, A. Nhanombe et al., “COVID-19 vaccine acceptability and its determinants in Mozambique: an online survey,” *Vaccines*, vol. 9, no. 8, p. 828, 2021.

J. S. S. Arce, S. Warren, N. Meriggii et al., “COVID-19 vaccine acceptance and hesitancy in low and middle income countries,” *Nature Medicine*, vol. 27, 2021.

C. Africa, “COVID-19 vaccine perceptions: A 15 country study,” 2021, https://africaedc.org/download/covid-19-vaccine-perceptions-a-15-country-study/.

Q. Wang, S. Xiu, S. Zhao et al., “Vaccine hesitancy: COVID-19 and influenza vaccine willingness among parents in wuxi, China—a cross-sectional study,” *Vaccines*, vol. 9, no. 4, p. 342, 2021.

M. Abedin, M. A. Islam, F. N. Rahman et al., “Willingness to vaccinate against COVID-19 among Bangladeshi adults: understanding the strategies to optimize vaccination coverage,” *PloS One*, vol. 16, no. 4, Article ID e0250495, 2021.

A. Zigron, A. A. Dror, N. G. Morozov et al., “COVID-19 vaccine acceptance among dental professionals based on employment status during the pandemic,” *Frontiers of Medicine*, vol. 8, Article ID 618403, 2021.

L. P. Wong, H. Alias, P.-F. Wong, H. Y. Lee, and S. AbuBakar, “The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay,” *Human Vaccines & Immunotherapeutics*, vol. 16, no. 9, pp. 2204–2214, 2020.

M. Trabucco Aurilio, F. S. Mennini, S. Gazzillo et al., “Intention to be vaccinated for COVID-19 among Italian nurses during the pandemic,” *Vaccines*, vol. 9, no. 5, p. 500, 2021.

A. Seydou, Who Wants COVID-19 Vaccination? In 5 West African Countries, Hesitancy Is High, Trust Low, Africa-Portal.org, Africa, 2021.

S. Al Ahdab, “A cross-sectional survey of knowledge, attitude and practice (KAP) towards COVID-19 pandemic among the Syrian residents,” *BMC Public Health*, vol. 21, pp. 296–297, 2021.

M. Kabamba Nzaji, L. Kabamba Ngombe, G. Ngoie Mwamba et al., “Acceptability of vaccination against COVID-19 among healthcare workers in the democratic republic of the Congo,” *Pragmatic and Observational Research*, vol. 11, pp. 103–109, 2020.

L. Williams, P. Flowers, J. McLeod, D. Young, and L. Rollins, “Social patterning and stability of intention to accept a COVID-19 vaccine in Scotland: who those most at risk accept a vaccine?” *Vaccines*, vol. 9, no. 1, p. 17, 2021.

D. Papagiannis, G. Rachiots, F. Malli et al., “Acceptability of COVID-19 vaccination among Greek health professionals,” *Vaccines*, vol. 9, no. 3, p. 200, 2021.

S. Neumann-Böhme, N. E. Varghese, I. Sabat et al., “Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19,” *European Journal of Health Economics*, vol. 21, pp. 977–982, 2020.

M. Detoc, S. Bruel, P. Frappe, B. Tardy, E. Botelho-Nevers, and A. Gagneux-Brunon, “Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic,” *Vaccine*, vol. 38, no. 45, pp. 7002–7006, 2020.

P. L. Reiter, M. L. Pennell, and M. L. Katz, “Acceptability of a COVID-19 vaccine among adults in the United States: how many people would get vaccinated?” *Vaccine*, vol. 38, no. 42, pp. 6500–6507, 2020.

S. Taylor, C. A. Landry, M. M. Paluszek, R. Groenewoud, G. S. Rachor, and G. J. G. Asmundson, “A proactive approach for managing COVID-19: the importance of understanding the motivational roots of vaccination hesitancy for SARS-CoV2,” *Frontiers in Psychology*, vol. 11, Article ID 575950, 2020.

O. V. Adeniyi, D. Stead, M. Singata-Madliki et al., “Acceptance of COVID-19 vaccine among the healthcare workers in the Eastern Cape, South Africa: a cross sectional study,” *Vaccines*, vol. 9, no. 6, p. 666, 2021.

S. Dzieciolowska, D. Hamel, S. Gadio et al., “Covid-19 vaccine acceptance, hesitancy, and refusal among Canadian healthcare workers: a multicenter survey,” *American Journal of Infection Control*, vol. 49, no. 9, pp. 1152–1157, 2021.